Â鶹ԼÅÄ

Almost two years into the pandemic, we’re still spending billions on Covid. But even in the midst of a new variant, are these billions being well spent?

The UK government boasted of being the first in the world to approve the Covid anti-viral drug Molnupiravir, but Newsnight investigates whether it can really deliver on early promises and whether when it comes to Covid the UK is spending wisely?

And what about the most recent approval of Sotrovimab, an antibody treatment for people with Covid that cuts the risk of severe illness?

Health Correspondent Deb Cohen reports.